Products

What will AGI do for Amosulalol?

This classification denotes an adrenergic antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C69JI1BAU8. European Medicines Agency schedules Amosulalol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05478MIG. Amosulalol generally arises in the molecular formula C18H24N2O5S. The term AMOSULALOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, no. 6, 1984, list 24.) AMOSULALOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule amosulalol under HS 29350090 and SITC 51580. As of Q4 2014, AMOSULALOL remains the US FDA Preferred Term for this commodity. Amosulalol bears US NLM identifiers UMLS ID C0103116 and NCI Concept Code C72916. SMILES: S(=O)(=O)(N)C1CC(C(O)CNCCOC2C(OC)CCCC2)CCC1C.

How AGI delivers it

Four ways AGI delivers for Amosulalol

  • Headless SaaS for Agents

    Give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

    For Amosulalol, give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

  • Services-as-Software

    Get the professional outcome delivered as software, priced on results, not headcount.

    For Amosulalol, get the professional outcome delivered as software, priced on results, not headcount.

Value flow

How Amosulalol connects

measured by

  • Assay Puritymodel
  • Chromatographic Impurity Profilemodel
  • Impurity Contentmodel
  • Optical Rotationmodel
  • Residual Solventmodel